SBO - Small Bowel ObstructionNCT06223620
A Multicenter Retrospective Review of Management Strategies in Small Bowel Obstruction
An observational study of SBO - Small Bowel Obstruction, run by Methodist Health System at 1 site in United States.
Trial summary
The objective of the study is to review performance of water soluble contrast study in patients admitted with Small Bowel Obstruction(SBO), will improve quality and safety, and decrease length of stay and morbidity. Read more about this study
- Who is it for?
- Ages 18 to 89 years
- Conditions the study is for
- SBO - Small Bowel Obstruction
- What is being tested?
- review performance of water soluble contrast
- How many people
- 504 participants
- Where
- 1 siteUnited States
- Study dates
- 30 Jul 2018to 31 Dec 2019
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 89 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Previous studies found on an average 3.9 to 9.4% patient suffer from SBO. The disease incidence varies depending on the cause of obstruction. Assuming that 3.9% of the patients will be affected by SBO, the study would require a sample size of 504 for estimating the expected proportion with 3% absolute precision and 95% confidence.
Who may be able to join
- • Adults aged 18-89 years of age
- Patients presenting with SBO
Who cannot join
- • Prisoners
- Pregnant women
Trial locations and contacts
1 site in 1 country.
United States1 site
Methodist Dallas Medical Center
Dallas, Texas, 75201
About this study
The objective of the study is to review performance of water soluble contrast study in patients admitted with Small Bowel Obstruction(SBO), will improve quality and safety, and decrease length of stay and morbidity.
Read the detailed description
Performance of contrast study has been a part of the protocols at multiple institutions of the southwestern surgical congress. Plan to perform a retrospective review of management protocols at these institutions. Wish to know whether the implementation of a standardized, protocol-driven pattern of practice involving the performance of water soluble contrast study in patients admitted with SBO, will improve quality and safety, and decrease length of stay and morbidity.
The objective of the study is to review performance of water soluble contrast study in patients admitted with SBO, will improve quality and safety, and decrease length of stay and morbidity.
Performance of contrast study has been a part of the protocols at multiple institutions of the southwestern surgical congress.
Hypothesize that implementation of a standardized, protocol-driven pattern of practice involving the performance of water soluble contrast study in patients admitted with SBO, will improve quality and safety, and decrease length of stay and morbidity.
- Conditions
- SBO - Small Bowel Obstruction
- Being tested
- review performance of water soluble contrast
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
review performance of water soluble contrastOther
review performance of water soluble contrast study in patients admitted with SBO, will improve quality and safety, and decrease length of stay and morbidity.
What is being measured
The primary outcome is the main question the study is designed to answer.
Morbidity and length of stay
Morbidity and length of stay
Measured: 1 year
Secondary outcomes (9)
Patient demographics
number of patients (age, sex, weight, height)
Measured: 1 year
admit date
Number of patients admitting to the hospital
Measured: 1 year
discharge date
number of patients discharging
Measured: 1 year
admission service
Number of services related to admissions
Measured: 1 year
Aspirin(ASA )class
number of aspirin class
Measured: 1 year
comorbidities
number of comorbidities associated
Measured: 1 year
surgical history
number of surgeries in the past
Measured: 1 year
labs
number of labs done
Measured: 1 year
time of contrast given
rate of Contrast given
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Jan 2024
- Study start30 Jul 2018
- Primary completion31 Dec 2019
- Study completion31 Dec 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for SBO - Small Bowel ObstructionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Retrospective
- Enrolment
- 504 participants (actual)
Sponsor and investigators
- Lead sponsor
- Methodist Health System
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Michael Truitt, MD, Principal investigator, The Methodist Hospital Research Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06223620
- Sponsor's protocol ID
- 046.GME.2018.D
- Status last verified
- Jan 2024
- First submitted
- 18 Oct 2023
- Last updated
- 24 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multicenter Retrospective Review of Management Strategies in Small Bowel Obstruction
- ClinicalTrials.gov ID
- NCT06223620
- Acronym / sponsor ID
- 046.GME.2018.D
- Conditions
- SBO - Small Bowel Obstruction
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 504 participants (actual)
- Lead sponsor
- Methodist Health SystemUniversity, hospital or other
- Study start
- 30 Jul 2018 (actual)
- Primary completion
- 31 Dec 2019 (actual)
- Study completion
- 31 Dec 2019 (actual)
- First posted
- 25 Jan 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of the study is to review performance of water soluble contrast study in patients admitted with Small Bowel Obstruction(SBO), will improve quality and safety, and decrease length of stay and morbidity.
Detailed description
Performance of contrast study has been a part of the protocols at multiple institutions of the southwestern surgical congress. Plan to perform a retrospective review of management protocols at these institutions. Wish to know whether the implementation of a standardized, protocol-driven pattern of practice involving the performance of water soluble contrast study in patients admitted with SBO, will improve quality and safety, and decrease length of stay and morbidity.
The objective of the study is to review performance of water soluble contrast study in patients admitted with SBO, will improve quality and safety, and decrease length of stay and morbidity.
Performance of contrast study has been a part of the protocols at multiple institutions of the southwestern surgical congress.
Hypothesize that implementation of a standardized, protocol-driven pattern of practice involving the performance of water soluble contrast study in patients admitted with SBO, will improve quality and safety, and decrease length of stay and morbidity.
Study design
- Observational model
- Other
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 to 89 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Previous studies found on an average 3.9 to 9.4% patient suffer from SBO. The disease incidence varies depending on the cause of obstruction. Assuming that 3.9% of the patients will be affected by SBO, the study would require a sample size of 504 for estimating the expected proportion with 3% absolute precision and 95% confidence.
Key inclusion criteria (2 listed)
- • Adults aged 18-89 years of age
Key exclusion criteria (2 listed)
- • Prisoners
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| review performance of water soluble contrastreview performance of water soluble contrast study in patients admitted with SBO, will improve quality and safety, and decrease length of stay and morbidity. | Other | – |
Primary outcome
Morbidity and length of stay
Time frame: 1 year
Morbidity and length of stay
9 secondary outcomes
Patient demographics
Time frame: 1 year
admit date
Time frame: 1 year
discharge date
Time frame: 1 year
admission service
Time frame: 1 year
Aspirin(ASA )class
Time frame: 1 year
comorbidities
Time frame: 1 year
surgical history
Time frame: 1 year
labs
Time frame: 1 year
time of contrast given
Time frame: 1 year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Mar 2026.
- Individual participant dataSharing planned: No
Related trials for SBO - Small Bowel Obstruction
Enrolling by invitationObservational study
Management of Non Emergency Adhesive Small Bowel Obstruction:
SBO - Small Bowel Obstruction
Recruiting
The Effect of Nasogastric Tube Placement on Complications in Patients With Small Bowel Obstruction - the SBO-TUBE Trial
Small Bowel Obstruction, Intestinal Obstruction and Ileus
Recruiting
GT Metabolic Magnet System in Adults With Gastrointestinal Disorders
Gastric Outlet Obstruction, Small Bowel Obstruction
RecruitingObservational study
Contribution of Point of Care Ultrasound by the Emergency Physician to Rule Out the Small Bowel Obstruction: a Diagnostic, Multicenter Study
Small Bowel Obstruction
Enrolling by invitationPhase 4
A Study of Intravenous Acetaminophen for Small Bowel Obstruction
Small Bowel Obstruction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Michael Truitt, MD principal investigator
The Methodist Hospital Research Institute
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of SBO - Small Bowel Obstruction, run by Methodist Health System at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Morbidity and length of stay (time frame: 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Mar 2026.